Orchid Pharma LimitedPharmaceuticals & HealthcareORCHPHARMA
Q1 FY27 concall · earnings callOrchid Pharma Limited
Quarterly revenue improved 15% year-over-year and EBITDA grew on better gross margins, but the core cephalosporin business continues to face intense industry pricing pressure.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue from Operations | ₹304 Cr | approx. 15% | |
| Combined Gross Margin | 33% | approx. 3% points | |
| EBITDA | ₹25 Cr | — | |
| AMS Division Revenue | ₹5 Cr | — | |
| AMS Division EBITDA Drag | ₹0.5 Cr | — |
Financials
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹217.34 Cr-1.5% YoY-2.4% QoQ | ₹20.78 Cr-29.4% YoY-23.7% QoQ | ₹4.10-33.7% YoY-23.6% QoQ |
| Q2 FY25 | ₹222.70 Cr+12% YoY-8.9% QoQ | ₹27.24 Cr+37.6% YoY-7.2% QoQ | ₹5.37+24.9% YoY-7.3% QoQ |
| Q1 FY25 | ₹244.41 Cr+33.6% YoY+12.6% QoQ | ₹29.35 Cr+212.2% YoY-11% QoQ | ₹5.79+213% YoY-15% QoQ |
| Q4 FY24 | ₹217.10 Cr+3.4% YoY-1.6% QoQ | ₹32.96 Cr-44.3% YoY+12% QoQ | ₹6.81-57.8% YoY+10.2% QoQ |
| Q3 FY24 | ₹220.59 Cr+38.1% YoY+11% QoQ | ₹29.43 Cr+287.7% YoY+48.6% QoQ | ₹6.18+232.3% YoY+43.7% QoQ |
TL;DR
- Revenue grew to INR304 crore, a 15% year-over-year increase.
- Combined gross margin improved by about 3 percentage points to 33%.
- EBITDA rose to INR25 crore from INR10 crore in the prior-year quarter.
- Industry overcapacity and cutthroat competition persist in the cephalosporin market.
- Integration savings from the Dhanuka merger are expected to start in the next financial year.
- Key projects, cefiderocol and 7-ACA backward integration, remain on schedule for commissioning by December 2026 and March 2027, respectively.
Said on the call
“In a number of important products and markets, both volumes and pricing were affected, with declines of 15% to 20% depending on the product.”
From the Q&A
| Topic | What management said |
|---|---|
| Market and Margin Outlook | Management expects continued competition in non-regulated markets and hopes for improved regulated market demand in the next few quarters, but sees Q1 as mediocre for regulated products. |
| 7-ACA Project Ramp-up | Ramp-up to 80%-100% utilization expected by end of first year; initial sales will be in-house with a long-term target of 80% captive use and 20% third-party sales. |
| Competitive Threat from China | Management believes 7-ACA prices have been stable for 10-12 years and Chinese companies, now mostly private, are focused on profit, reducing the likelihood of drastic price dumping. |
| Exblifep (Cefepime-Enmetazobactam) Sales | International sales currently supplied from a CMO in China; Orchid plans to eventually get its own site registered and supply partially from its own facilities. |
| Capital Expenditure | Capex for FY27 includes INR750 crores for 7-ACA and USD20 million to USD25 million for cefiderocol; no significant capex planned for the next financial year after these projects are completed. |
| Product Mix and Strategy | Management is focused on a value-based, diversified portfolio strategy and de-risking from competitive API business through backward integration (7-ACA) and forward integration (injectables). |
Guidance
- Initial benefits from merger integration initiatives are expected to begin becoming visible in the next financial year.
- Cefiderocol facility commissioning is targeted for December 2026, with validation and initial batches from January to March 2027.
- 7-ACA project aims for commissioning and first commercial batch by March 2027.
- No yearly revenue growth guidance was provided for FY27.
- Exblifep (Enmetazobactam) lifetime sales potential remains $1.1 billion to $2 billion.
- For 7-ACA, long-term utilization guidance is 80% in-house use and 20% third-party sales.
Source
Summary written from the transcript filed by Orchid Pharma Limited for the call held on 21 Aug 2026; published 24 Aug 2026, 18:33 IST.
More Q1 FY27 concalls ·How verification works ·Report an error